On the other hand, dabrafenib was shown to have a dose-dependent activity only towards A375 cells, but, because this drug primarily targets melanoma associated with a mutation in the BRAF gene [48], and A375 was the only melanoma cell line included in the study, the obtained results indicate the precision of the present analyses. The gene discussed is BRAF; the disease is melanoma.